Andrographis paniculata extract: Clinical Trials

5 trials of Andrographis paniculata extract, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 unknown. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Completed 2, Terminated 2, Unknown 1

Follow Andrographis paniculata extract: new trials by email Literature Review of Andrographis paniculata extract trials Research Report on Andrographis paniculata extract

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19
Andrographis Paniculata, Boesenbergia, Standard supportive treatment - Covid19
Phase 3UnknownMahidol University30602021-08-302021-09-09
To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI
A. Paniculata, A. Chilensis, A. Paniculata and A. Chilensis - Upper Respiratory Tract Infection
Phase 3CompletedVedic Lifesciences Pvt. Ltd.2252021-03-202022-05-10
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer
Andrographis Paniculata - Squamous Cell Carcinoma of Esophagus
Phase 3CompletedChinese University of Hong Kong302018-03-012021-11-08
HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
HMPL-004, Placebo - Ulcerative Colitis
Phase 3TerminatedHutchison Medipharma Limited662013-06-012020-01-13
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day - Ulcerative Colitis
Phase 3TerminatedHutchison Medipharma Limited2012013-03-012020-01-02

Conditions studied

Colitis, Ulcerative (2)  ·  COVID-19 (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Lymphoma, Follicular (1)  ·  Motor Activity (1)  ·  Respiratory Tract Infections (1)

Sponsors

Hutchison Medipharma Limited (2)  ·  Chinese University of Hong Kong (1)  ·  Mahidol University (1)  ·  Vedic Lifesciences Pvt. Ltd. (1)

Countries

United States (2)  ·  China (1)  ·  India (1)  ·  Thailand (1)

Top investigators

Liu Rongjun, Dr. (1)  ·  Philip WY Chiu, MD (1)  ·  Rongjun Liu, MD (1)